Katheryn A. Bell

Katheryn A. Bell

Auto-generated profile, based on publicly available information

Katheryn A. Bell

Georgetown University School of Medicine, Washington, DC, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2020 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
KBKatheryn A. Bell
Katheryn A. Bell
CBCaitlin M. Brumfiel
Caitlin M. Brumfiel
WHWasim Haidari
Wasim Haidari
LBLaura Boger
Laura Boger
Objective: This article reviews clinical trials to assess the efficacy, safety, and clinical application of trifarotene 0.005% cream (Aklief). Data Sources: A systematic review of the literature was performed using the terms trifarotene OR Aklief OR CD5789 in MEDLINE (PubMed) and EMBASE databases. Articles prior to May 2020 were considered for inclusion. Bibliographies and ClinicalTrials.gov were also searched to identify further studies. Study Selection and Data Extraction: Relevant English language and human studies related to pharmacology, clinical trials, and safety were considered. Data Synthesis: In the 52-week phase III trial, treatment success rates for facial acne (Investigator Global Assessment [IGA] rating of no or almost no acne) and truncal acne (Physician’s Global Assessment [PGA] rating of no or almost no acne) were 65.1% and 66.9%, respectively. Overall success rates (IGA and PGA success in the same patient) were 57.9%; 52.8% of patients had a Dermatology Quality of Life Index score of 0 or 1, compared with 22.6% at baseline. Trifarotene was well tolerated, with pruritus, irritation, and sunburn as the most common adverse effects. Relevance to Patient Care and Clinical Practice: Trifarotene is a newly Food and Drug Administration–labeled fourth-generation topical retinoid that shows particular promise in the treatment of facial and truncal acne vulgaris. It is an effective and safe addition to currently available retinoids. Conclusion: Trifarotene is effective and safe for treatment of facial and truncal acne. Future trials should compare its efficacy and tolerability with that of the older, clinically established retinoids. Despite efficacy, cost may be a prohibitive factor.

16 November 2020 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
KBKatheryn A. Bell
Katheryn A. Bell
EBEsther A. Balogh
Esther A. Balogh
SFSteven R. Feldman
Steven R. Feldman
Introduction: Estimates of the prevalence of comorbid depression vary, ranging from 9 and 62%. Deterioration of mental health may emerge as a result of psoriasis; however, it is theorized that depression alone may independently predispose patients to new-onset psoriasis. Areas covered: The aim of this brief review is to explore the impact of depression on psoriasis treatment. Expert opinion: The two studies that directly assess the role of depression in psoriasis treatment outcomes are important, as unaddressed depression can undermine the success of a given treatment. This may reflect the notion that depressed individuals are less likely to be adherent. Thus, it may be valuable for clinicians to not only screen for depression, but to ensure that it is adequately treated. Our knowledge of treatment preferences in psoriasis patients with comorbid depression is limited. Expanding our understanding of preferences may allow providers to better align their recommendations to ultimately increase adherence. Additionally, given that many psoriasis treatments have an impact on depression, it may be beneficial for clinicians to evaluate patients for psychiatric risk factors to optimize the treatment regimen.

1 July 2021 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
CBCaitlin M Brumfiel
Caitlin M Brumfiel
MPMeera H Patel
Meera H Patel
KBKatheryn A Bell
Katheryn A Bell
MCMichael A Cardis
Michael A Cardis
Acne vulgaris is a common skin condition of the face and trunk that negatively impacts quality of life. Trifarotene is a new first-in-class fourth-generation topical retinoid that has been uniquely studied in the treatment of both facial and truncal acne. Through selective agonism of retinoic acid receptor (RAR)-gamma, the most predominant RAR isotype in the epidermis, trifarotene exerts more targeted, skin-specific effects than earlier generation retinoids. This narrative review summarizes all currently available literature regarding the use of trifarotene in acne vulgaris. We focus on efficacy, safety, and tolerability data and highlight quality of life outcomes and patient-reported satisfaction. Future clinical trials and the clinical applicability of this novel medication in the treatment of acne are also discussed.

15 November 2020 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
RGRima Ghamrawi
Rima Ghamrawi
KBKatheryn A. Bell
Katheryn A. Bell
EBEsther A. Balogh
Esther A. Balogh
LSLindsay C. Strowd
Lindsay C. Strowd
Steven R. FeldmanSteven R. Feldman
Steven R. Feldman
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by erythematous lesions, pruritus, and a skin barrier defect. Long-term treatment in children is challenging, as there ...

4 August 2020 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
KBKatheryn A. Bell Ba
Katheryn A. Bell Ba
KSKarl M. Saardi
Karl M. Saardi
SNScott A. Norton
Scott A. Norton
KHKaiane A. Habeshian
Kaiane A. Habeshian

1 December 2020 in JAAD Case Reports
Verified
Journal Article
Open access
KBKatheryn A. Bell
Katheryn A. Bell
KSKarl Saardi
Karl Saardi
PAPaloma Alejandro
Paloma Alejandro
LBLaura Boger
Laura Boger